Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce H Morimoto

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Journal of Alzheimer'S Disease : JAD|April 21, 2020
A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's DiseaseSamuel T Henderson, Bruce H Morimoto, Jeffrey L Cummings, et al.
Neuropsychiatric Disease and Treatment|February 21, 2012
Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsyMichael Gold, Stefan Lorenzl, Alistair J Stewart, et al.
Journal of Alzheimer'S Disease Reports|November 28, 2018
Pharmacokinetics in Rat of P8, a Peptide Drug Candidate for the Treatment of Alzheimer's Disease: Stability and Delivery to the BrainNazneen N Dewji, Marc R Azar, Leah R Hanson, et al.
Pharmacology Research & Perspectives|December 16, 2014
Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synucleinIddo Magen, Regina Ostritsky, Franziska Richter, et al.
CNS Drug Reviews|April 15, 2006
NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)Illana Gozes, Bruce H Morimoto, Jacqueline Tiong, et al.
Parkinsonism & Related Disorders|May 14, 2016
Predicting disease progression in progressive supranuclear palsy in multicenter clinical trialsJee Bang, Iryna V Lobach, Anthony E Lang, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 17, 2011
Revision of the criteria for Alzheimer’s disease: A symposiumSteven T DeKosky, Maria C Carrillo, Creighton Phelps, et al.
The Lancet. Neurology|May 31, 2014
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trialAdam L Boxer, Anthony E Lang, Murray Grossman, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Alzheimer'S Disease : JAD|April 21, 2020
A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's DiseaseSamuel T Henderson, Bruce H Morimoto, Jeffrey L Cummings, et al.
Neuropsychiatric Disease and Treatment|February 21, 2012
Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsyMichael Gold, Stefan Lorenzl, Alistair J Stewart, et al.
Journal of Alzheimer'S Disease Reports|November 28, 2018
Pharmacokinetics in Rat of P8, a Peptide Drug Candidate for the Treatment of Alzheimer's Disease: Stability and Delivery to the BrainNazneen N Dewji, Marc R Azar, Leah R Hanson, et al.
Pharmacology Research & Perspectives|December 16, 2014
Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synucleinIddo Magen, Regina Ostritsky, Franziska Richter, et al.
CNS Drug Reviews|April 15, 2006
NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)Illana Gozes, Bruce H Morimoto, Jacqueline Tiong, et al.
Parkinsonism & Related Disorders|May 14, 2016
Predicting disease progression in progressive supranuclear palsy in multicenter clinical trialsJee Bang, Iryna V Lobach, Anthony E Lang, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 17, 2011
Revision of the criteria for Alzheimer’s disease: A symposiumSteven T DeKosky, Maria C Carrillo, Creighton Phelps, et al.
The Lancet. Neurology|May 31, 2014
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trialAdam L Boxer, Anthony E Lang, Murray Grossman, et al.
Pageof 2